Here, the authors identify activation of PI3K/mTOR and CREB pathways as a driver of GC-resistance in BCP-ALL and restore sensitivity using the multi kinase inhibitor, dasatinib. This evidence concerns the gene MTOR and acute lymphoblastic leukemia.